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• Obesity & CVD are increasing rapidly in Africa 
• Low cost measures are needed to find those at risk 
• Debate continues on the optimum Waist Circumference threshold for African adults. 
• Waist-to-height ratio predicts current & future CVD risk in South-African adults. 
• There is greater global agreement on the WHtR threshold (>0.5) for risk. 
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ABSTRACT  1 
Background and aims 2 
Simple, low-cost central obesity measures may help identify individuals with increased 3 
cardiometabolic disease risk, although it is unclear which measures perform best in African 4 
adults. We aimed to: 1) cross-sectionally compare the accuracy of existing waist-to-height 5 
ratio (WHtR) and waist circumference (WC) thresholds to identify individuals with 6 
hypertension, pre-diabetes, or dyslipidaemia; 2) identify optimal WC and WHt  thresholds to 7 
detect CVD risk in this African population; and 3) assess which measure best predicts 5-year 8 
CVD risk. 9 
Methods and results  10 
Black South Africans (577 men, 942 women, aged > 30years) were recruited by random 11 
household selection from four North West Province communities. Demographic and 12 
anthropometric measures were taken. Recommended diagnostic thresholds (WC >80 cm for 13 
women, >94 cm for men; WHtR > 0.5) were evaluated to predict blood pressure, fasting 14 
blood glucose, lipids, and glycated haemoglobin measured at baseline and 5 year follow up. 15 
Women were significantly more overweight than men at baseline (mean body mass index 16 
(BMI) women 27.3 + 7.4 kg/m2, men 20.9 + 4.3 kg/m2; median WC women 81.9 cm 17 
(interquartile range 61–103),  men 74.7 cm (63-87cm), all P < 0.001). In women, both WC 18 
and WHtR significantly predicted all cardiometabolic risk factors after 5 years. In men, even 19 
after adjusting WC threshold based on ROC analysis, WHtR better predicted overall 5-year 20 
risk. Neither measure predicted hypertension in men.    21 
Conclusions 22 
The WHtR threshold of >0.5 appears to be more consistently supported and may provide a 23 
better predictor of future cardiometabolic risk in Sub-Saharan Africa.  24 
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 1 
INTRODUCTION 
Some of the most rapid increases in obesity and the associated cardiometabolic disease are 2 
currently occurring in sub-Saharan Africa (SSA) (1, 2) creating a growing demand for 3 
suitable tools that can be employed to determine risk.  Measures of central obesity, such as 4 
waist circumference (WC) and waist-to-height ratio (WHtR), are simple to collect, 5 
appropriate for low-resource settings, and better discriminators of cardiovascular disease 6 
(CVD) risk than body mass index (BMI)(3). However, it is unclear which markers of central 7 
obesity perform best in SSA adults to predict CVD.  8 
Current recommended diagnostic thresholds for WC in Africa from the World Health 9 
Organisation (WHO; WCWHO > 94 cm for men, > 80 cm for women) (4) are based 10 
predominantly on prospective analyses in Caucasian reference populations. However, recent 11 
evidence from cross-sectional studies in SSA would suggest that these may not be 12 
appropriate for African populations (5-10) and ethnicity specific thresholds (such as those 13 
recommended for Asian populations (4)) may be required. While the recommended WHtR 14 
threshold of 0.5 has largely been determined from Caucasian and Asian populations, (11, 12), 15 
this WHtR threshold requires validation in SSA populations.  16 
The aims of this study were: 1) To compare the accuracy of existing WC and WHtR 17 
thresholds to cross-sectionally identify individuals with hypertension, pre-diabetes, or 18 
dyslipidaemia; 2) to determine the optimal WC and WHtR thresholds for detection of these 19 
CVD risk factors in an African population; and 3) to determine whether these thresholds 20 
prospectively predict 5-year CVD risk. 21 
 22 
 23 
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 1 
METHODS 2 
Study population 3 
The Prospective Urban Rural Epidemiology (PURE) study is a multinational cohort study 4 
examining the environmental, societal and biological determinants of obesity and chronic 5 
health problems. Study design, methodology, and specific recruitment procedures for PURE 6 
South Africa are described in detail elsewhere (13, 14). In brief, the first South African cohort 7 
began in 2005, with 5 year follow-up (2010). Black African men and women (n = 2010, age 8 
> 30 years, no previous HIV diagnosis) were recruited from 6000 randomly selected 9 
households in two urban (n = 1004, 60 % female) and two rural (n = 1006, 65 % female) 10 
North West Province communities. Trained fieldworkers speaking the participants’ home 11 
languages (predominantly Setswana) were used and all participants provided written 12 
informed consent prior to taking part in the study. Participants were followed up in 2010. The 13 
study complied with the ethical principles for medical research involving human subjects as 14 
stated in the Declaration of Helsinki (15) and was approved by the North-West University 15 
Ethics Committee.  16 
Measurements 17 
Height (without shoes) was measured to the nearest 0.1 cm with a stadiometer (SECA, 18 
Hamburg Germany). Weight in light clothing was measured to the nearest 0.01 kg on 19 
portable electronic scales (A&D Medical, Abingdon UK). WC was measured midway 20 
between the iliac crest and the lower margin of the last palpable rib in the mid-axillary line 21 
using a steel anthropometric tape measure (Lufkin, Apex USA). BMI and WHtR were 22 
calculated using the formulae BMI = weight (kg)/height (m)2 and WHtR = WC (cm)/height 23 
(cm), respectively.  24 
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Blood samples were drawn at the antecubital fossa following an overnight fast. Plasma 1 
glucose, serum high-density lipoprotein (HDL)-cholesterol and triglyceride concentrations 2 
were determined using two Sequential Multiple Analyser Computers (Cobas Integra 400 plus, 3 
Roche, Basel Switzerland; Konelab 20i, Thermo Scientific, Finland). Glycated haemoglobin 4 
(HbA1c) was analysed using the D-10 Hemoglobin Testing System (Bio-Rad Laboratories, 5 
Hercules USA). Human Immunodeficiency Virus (HIV) status was determined with the First 6 
Response (PMC Medical, Nani Daman India) rapid HIV card test using whole blood.  If 7 
positive, the test was repeated with the Pareeshak (BHAT Bio-tech, Bangalore India) card 8 
test.  Following 10 minutes rest, systolic (SBP) and diastolic blood pressure (DBP) were 9 
measured on the right upper arm using an automated monitor (HEM-757, Omron Healthcare, 10 
Tokyo Japan) and appropriate size cuff and participants seated with their arm supported at the 11 
level of the heart. A second BP measure taken after 5 minutes was used for analysis. 12 
Metabolic risk factor definitions  13 
The diagnostic criteria for elevated CVD risk were: hypertension (SBP > 140 mmHg and/or 14 
DBP > 90 mmHg or on antihypertensive treatment); low HDL-C (< 1 mmol/l in men, < 1.3 15 
mmol/l in women); elevated triglycerides (TG > 1.7 mmol/l or 150 mg/dl); impaired fasting 16 
glucose (IFG > 5.6 mmol/l or 100 mg/dl); elevated HbA1c with high risk of developing 17 
diabetes (HbA1c > 6.0% or 42 mmol/mol) (WHO, International Society of Hypertension, 18 
International Diabetes Federation, American Heart Association and American Diabetes 19 
Association guidelines (16-20)).  20 
Statistical methods 21 
Statistical analyses were performed using Stata version 13 (StataCorp, Texas, USA). 22 
Participants that were pregnant (n = 13), tested positive for HIV (n = 320) or with missing 23 
data (n = 158), were excluded from baseline analysis. Normality of variables was checked 24 
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with visual inspection of histogram plots and the Shapiro-Wilk test. Differences between men 1 
and women in the remaining baseline sample (n = 1,519) were analysed by independent t-test 2 
for normally distributed data and the Mann-Whitney U test for non-normally distributed data 3 
for continuous variables. The Chi Square test was used for categorical variables. Analyses 4 
were considered statistically significant at P < 0.05. Receiver Operator Characteristic (ROC) 5 
curves and Youden’s Index (J = sensitivity + specificity - 1) were used to assess diagnostic 6 
test performance (21) and identify WC and WHtR thresholds predicting baseline metabolic 7 
risk in men and women separately. Poor measures with ROC area under the curve (AUC) < 8 
0.60 (22) were excluded. 9 
At 5-year follow-up, 477 participants were lost to follow up (30 % had died, 26 % moved, 31 10 
% refused, 13 % unable to contact). Participants testing positive for HIV at follow-up (n = 11 
59), pregnant (n = 6), or with missing data were excluded leaving n = 917 with complete 12 
data. Any participant classified with a baseline metabolic risk factor was excluded from 13 
subsequent prospective analyses for that risk factor. Logistic regression models were used to 14 
estimate the odds of developing each metabolic risk factor in 2010 using the WC and WHtR 15 
diagnostic thresholds identified at baseline. Men and women were analysed separately 16 
adjusting for age, baseline smoking status, alcohol consumption and menopausal status 17 
(women only). Backwards selection procedure was used to select the covariates. Likelihood 18 
ratio tests were used to determine whether WC and WHtR diagnostic thresholds should be 19 
included in the logistic regression models. Odds ratios (ORs) and 95% confidence intervals 20 
(CIs) for each diagnostic threshold were computed for each metabolic risk factor from the 21 
multiple logistic regression models.  22 
 23 
 24 
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RESULTS 1 
Participant characteristics 2 
Table 1 shows baseline characteristics of the participants (577 men, 942 women). 3 
Employment levels were low and 78 % of all adults had either no education or were only 4 
educated until primary school level. Women had a higher BMI, WC and WHtR than men (P 5 
< 0.001) and a more unfavourable metabolic profile (higher prevalence of IFG, elevated 6 
HbA1c, elevated triglycerides and low HDL-C). Prevalence of hypertension was above 50 % 7 
in both genders, although men displayed higher mean SBP (P < 0.001) with higher use of 8 
tobacco (61% vs. 27%) and alcohol (60% vs. 28%). More women were on anti-hypertension 9 
medication (14 % vs. 6 %) than men, but median ‘on treatment’ SBP values suggest that BP 10 
management was not optimal in either group. Due to the gender differences observed, all 11 
subsequent analyses were conducted separately for men and women. 12 
Cross-sectional analysis of WC, WHtR and cardiometabolic disease 13 
Classification of participants as “at risk” by either WCWHO (37 %, n = 555) or by WHtR0.5 (44 14 
%, n = 674) at baseline showed the two central obesity measures to not identify the same 15 
individuals. While most individuals with high WC also had high WHtR (97 % of women, 100 16 
% of men), there were , fewer individuals with a high WHtR and simultaneous high WC (92 17 
% of women and only 29% of men).  More than 75 % of men with any of the metabolic risk 18 
factors had a waist circumference below the WHO threshold of 94 cm (Table 2). WHtR 19 
performed better to identify cases of risk in men although, with the exception of elevated 20 
triglycerides, over 50 % of men with an elevated risk factor also had a WHtR < 0.5. In 21 
contrast, both thresholds (WCWHO and WHtR0.5) identified more than 65 % of women with 22 
elevated metabolic risk, with WHtR performing marginally better than WC for all CVD risk 23 
factors.  24 
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 In men, there were no significant differences between WC and WHtR to identify risk of 1 
diabetes or dyslipidaemia but neither measure predicted hypertension (Table 3). In women, 2 
both WC and WHtR predicted all markers of metabolic risk, with a small but significant 3 
difference between WC and WHtR for low HDL-C (P=0.004). ROC analysis confirmed the 4 
optimal threshold for WHtR to be the recommended threshold (>0.5) in both men and 5 
women. In contrast, only the WHO WC recommendation for women (>80cm) was supported 6 
by ROC analysis while the optimal WC threshold to predict risk in men was found to be 80 7 
cm (much lower than the WHO WC threshold of 94cm).   8 
Prediction of 5 year metabolic risk development by WC and WHtR 9 
Table 4 shows the OR (95 % CI) for 5-year metabolic risk by recommended and ROC 10 
identified optimal WC and WHtR thresholds in those with normal metabolic risk profile at 11 
baseline. Women with a WC>80 cm or WHtR>0.5 in 2005, had a significantly increased 12 
probability of developing all metabolic risk factors over 5 years after adjustment for age, 13 
smoking status, alcohol intake and menopausal status.  14 
In men, the current recommended WHO threshold for waist circumference (> 94 cm) showed 15 
the worst performance in predicting 5 year cardiometabolic risk. Reducing this WC threshold 16 
to > 80 cm (WCPURE) resulted in the significant prediction of impaired fasting glucose, HDL-17 
C, and triglycerides but not HbA1c or hypertension.  While WHtR could also not predict 18 
hypertension in men, WHtR>0.5 was a significant predictor of all other metabolic risk factors 19 
over 5 years.  20 
 21 
 22 
 23 
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DISCUSSION 1 
To our knowledge, this is the first prospective study to investigate which central obesity 2 
measures best predict future CVD risk in sub-Saharan African adults. The results suggest that 3 
WHtR0.5 significantly and most consistently predicted 5-year cardiometabolic risk. The only 4 
exception was for the prediction of hypertension in men, where neither WC nor WHtR were 5 
able to predict the outcome. This may be in part due to high hypertension prevalence in this 6 
group (only 27% of men remained hypertension-free over 5 years). Similar hypertension 7 
prevalence between men and women despite differences in levels of obesity has previously 8 
been observed in South African populations (23) suggesting the relationship between obesity 9 
and hypertension development in men is confounded by other factors such as smoking and 10 
alcohol use, both significant in our logistic regression models. Alcohol intake in particular 11 
has previously been shown to be an important predictor of hypertension development in this 12 
group (24). 13 
Identifying optimal WC thresholds for SSA adults is challenging without large, randomly 14 
selected cohorts and previous studies have recommended a number of different thresholds. 15 
One study in black South African teachers (n = 81 men, n = 90 women, aged 25–65 years) 16 
recommended higher WC thresholds (90–96 cm for men, 92–98 cm for women) (8). Another 17 
study of black South African mothers in Soweto (n = 1180, mean age 40 + 10.6 years, 50.1 % 18 
obese) also suggested the WC threshold should be higher at > 91.5 cm, 90.1 cm and 87.6 cm 19 
to predict metabolic syndrome, elevated BP (> 135/85 mmHg), and low HDL-C respectively 20 
(9). In both these studies, men and women had higher mean BMI and waist circumference 21 
measures than those observed in our current study, most likely contributing to the higher WC 22 
cut-point recommendations. Other studies present similar results to our own, with optimal 23 
thresholds for predicting elevated blood pressure (WC > 80-80.5 cm, WHtR > 0.53-0.57), 24 
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elevated fasting blood glucose (WC > 81.5 cm, WHtR > 0.51), and low HDL-C (WC > 77 1 
cm, WHtR > 0.47) reported for pre-menopausal black South African women and Ghanaian 2 
women (6, 10). However, previous studies are based on cross-sectional data and, even after 3 
optimising WC threshold based on our ROC analysis (WCPURE), WC could only predict 5 4 
year risk of three of the five cardiovascular risk factors in men.  5 
While disagreement surrounds the optimal WC threshold for predicting metabolic risk in SSA 6 
adults, our confirmation of the optimal threshold for WHtR at > 0.5 appears more 7 
consistently supported. Although limited studies have reported varied optimal WHtR 8 
thresholds ranging from 0.45-0.65 (25-28), both meta-analysis and systematic reviews 9 
confirm the WHtR threshold of >0.5
 
across Caucasian, Asian and Central American 10 
populations and
 
indicate WHtR may be a better discriminator than WC or BMI for metabolic 11 
risk in adults, children, both genders and varying ethnic groups (3, 11, 12). WHtR, like WC, 12 
is cheap and easy to obtain, but can also be used with imperial or metric values, and use of 13 
the 0.5 threshold promotes a simple public health message “Keep your waist circumference to 14 
less than half your height”(29).  15 
Limitations of this study are the generalizability of results to other populations in sub-16 
Saharan Africa. As there are few prospective SSA population-based studies, this study both 17 
developed the thresholds in the cross-sectional data and then applied the thresholds 18 
prospectively in a sub-set of the population, who were free of the metabolic risk factor at 19 
baseline.  Further application to other SSA prospective studies is needed to determine how 20 
well these thresholds predict long-term CVD risk. For this same reason, use of the lower WC 21 
threshold identified in men in this sample is not recommended and there is already great 22 
variability in the literature on an “optimal” WC threshold for identifying CVD risk. While 23 
WHtR0.5 appears more consistently supported within and between countries, further large 24 
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prospective studies are required in SSA. Our sample did have higher unemployment rates 1 
than those reported for the province generally (45 %;(30)) possibly indicating a bias with 2 
employed persons being less available during the working week to participate in the study. 3 
Although it could be argued this population (low levels of employment; very little education) 4 
are those most vulnerable and in need of simple measures that can be used in targeting 5 
interventions to reduce non-communicable disease. A further limitation of the results is the 6 
exclusion of participants living with HIV as this does not present a real evaluation of sub-7 
Saharan African populations. However, previous cross-sectional analysis of central obesity 8 
and CVD risk in this population including those living with HIV supports our findings (31). 9 
Furthermore, no adjustment was made for physical activity and dietary factors. These may 10 
also be important risk factors for CVD in this population. However, as the exposure of 11 
interest was the central obesity measure, we did not include physical inactivity and dietary 12 
factors in the models as they are major contributors to energy imbalance and thus central 13 
obesity.  14 
Incorporating height into an assessment of central obesity may confer additional information 15 
about risk. Previous studies have determined a strong independent association between height 16 
and stroke risk (32), and coronary heart disease (33) whereby increased height appears 17 
protective. More recently, growth and timing of peak height velocity have also been 18 
associated with adult cardiovascular disease mortality (34). While these findings have yet to 19 
be confirmed in SSA, they may imply that adjusting central obesity measures for height 20 
provides a better indicator of the dynamic biopsychosocial factors involved in the relationship 21 
between body composition and cardiovascular risk than, for example, ethnicity adjusted WC 22 
cut-points, especially in countries undergoing rapid urbanisation and socioeconomic 23 
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transition. Incorporating height into the central obesity assessment may also be likely to 1 
reduce the variability observed between populations due to differences in height.  2 
 3 
Conclusions 4 
Our findings from this large cohort study investigating the prospective association between 5 
WC, WHtR and the development of metabolic risk support the use of the recommended 6 
single waist-to-height ratio threshold of 0.5 to predict the development of cardiometabolic 7 
disease in sub-Saharan African men and women. In comparison to waist circumference 8 
measures, waist-to-height ratio (>0.5) appears more consistently supported to detect 9 
cardiovascular risk across populations on the African continent. 10 
 11 
 12 
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TABLE 1 
Baseline characteristics of the study group (n=1,519) by gender 1 
 
 Men Women P 
n (%) 577 (38) 942 (62)  
Age in years 51.2 + 10.5 50.7 + 10.3 0.4 
Weight in kg 58.6+ 12.6 67.0 + 18.6 <0.001 
Height in cm 167.3 + 7.0 156.5 + 6.4 <0.001 
BMI in kg/m2 20.9 + 4.3 27.3 + 7.4 <0.001 
Waist circumference in cm, median (IQR) 74.7 (12.3) 81.9 (20.6) <0.001 
Waist-to-Height Ratio 0.46 + 0.006 0.53 + 0.09 <0.001 
Smokers, n (%) 350 (61) 440 (47) <0.001 
Alcohol consumers, n (%) 344 (60) 260 (28) <0.001 
In employment, n (%) 64 (12) 78 (9) 0.07 
Educated to primary school or less, n (%) 448 (77.6) 735 (78) 0.862 
Resident in rural community, n (%) 264 (46) 489 (52) 0.02 
Cardiovascular measures, median (IQR)    
    Systolic blood pressure in mmHg* 133.5 (29) 128.0 (31) <0.001 
    Diastolic blood pressure in mmHg* 86.0 (19.5) 87.0 (18.0) 0.2829 
    Fasting blood glucose in mmol/l† 4.8 (1.0) 4.9 (1.0) 0.0038 
    HbA1c % (mmol/mol†) 5.5 (0.5); 37 
(5.5) 
5.6 (0.6); 38 
(6.6) 
<0.001 
    Total triglyceride  in mmol/l‡  0.97 (0.64) 1.15 (0.82) <0.001 
    HDL cholesterol in mmol/l‡  1.55 (0.89) 1.44 (0.73) 0.001 
Medication use, n (%)    
    Diabetes medication  3 (0.5) 15 (1.6)  
    Hypertension medication 37 (6.4) 127 (13.5)  
      On treatment SBP in mmHg median 
(IQR) 
143 (110-176) 140 (104-176)  
      On treatment DBP in mmHg median 
(IQR) 
90 (72-108) 93 (76-110)  
Metabolic risk factors, n (%)    
    Hypertension (SBP >140 and/or DBP >90 
mmHg) 
297 (52) 511 (54) 0.293 
    Impaired fasting glucose (>5.6 mmol/l) 109 (19) 227 (24) 0.018 
    Elevated HbA1c (>6%, >42 mmol/l) 74 (13) 234 (25) <0.001 
    Elevated triglyceride (>1.7 mmol/l) 84 (15) 222 (24) <0.001 
    Low HDL-C (men<1.0 mmol/l, 
women<1.3 mmol/l) 
90 (16) 372 (40) <0.001 
 
                                                            
1
 Data are presented as means +SD unless otherwise indicated, IQR is interquartile range.  
P values are for comparison between men and women. 
Excluding those on antihypertensive medication*, medication for type 2 diabetes†, or 
cholesterol lowering medication‡. 
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TABLE 2 
Distribution of cardiovascular disease risk factors in relation to recommended diagnostic 
thresholds for waist circumference and waist-to-height ratio2 
 
 Cardiovascular disease risk factors 
 Hypertension Elevated 
triglyceride 
Low  
HDL-C 
Impaired 
fasting 
glucose 
Elevated 
HbA1c 
Measure of central obesity: n (% of total cases) 
Men (n=577)      
    Waist Circumference 
WHO 
     
       <94 cm (n=542) 271 (91%) 65 (77%) 75 
(83%) 
94 (86%) 59 (80%) 
       >94 cm (n=35) 26 (9%) 19 (23%) 15 
(17%) 
15 (14%) 15 (20%) 
    Waist-to-height ratio      
       <0.5 (n=454) 215 (72%) 34 (40%) 54 
(60%) 
67 (62%) 38 (51%) 
       >0.5 (n=123) 82 (28%) 50 (60%) 36 
(40%) 
42 (39%) 36 (49%) 
Women (n=942)      
    Waist Circumference 
WHO 
     
       <80 cm (n=422) 181 (35%) 60 (27%) 121 
(32%) 
75 (33%) 55 (24%) 
       >80 cm (n=520) 330 (65%) 162 (73%) 251 
(68%) 
152 
(67%) 
179 
(76%) 
    Waist-to-height ratio      
       <0.5 (n=391) 156 (30%) 54 (24%) 117 
(31%) 
68 (30%) 51 (22%) 
       >0.5 (n=551) 355 (70%) 168 (76%) 255 
(69%) 
159 
(70%) 
183 
(78%) 
 
 
 
 
 
 
 
 
 
 
 
                                                            
2
 WHO, World Health Organization; HDL-C, high density lipoprotein cholesterol; HbA1c, 
glycated haemoglobin 
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TABLE 3 
Waist circumference and waist-to-height ratio thresholds for metabolic risk variables in black South African men and women3 
 
 Men (n=577)       Women (n=942)      
 ROC   P 
value 
Optimal Optimal  Optimal  Youden  ROC   P 
value 
Optimal Optimal  Optimal  Youde
n 
 AUC  95% CI (vs. 
WC) 
threshold sensitivity 
(%) 
specificity 
(%) 
J 
Value* 
 AUC  95% CI (vs. 
WC) 
Threshol
d 
sensitivity 
(%) 
specificity 
(%) 
J 
Value* 
                
Hypertension (SBP >140 or DBP >90 mmHg or taking antihypertensive medication) 
WC (cm) <0.6†      0.64 0.60-0.67  78.5 68.9 53.1 0.2202 
WHtR <0.6†      0.64 0.60-0.67 0.63 0.51 67.7 56.8 0.2456 
 
Elevated Triglycerides (>1.7 mmol/l) or on triglyceride lowering medication 
WC (cm) 0.79 0.73-0.84  78.5 76.2 73.0 0.492  0.66 0.62-0.70  78.6 77.0 47.2 0.2425 
WHtR 0.78 0.73-0.83 0.53 0.5 59.5 86.0 0.455  0.66 0.62-0.70 0.65 0.52 68.0 56.4 0.2441 
 
Low HDL-C (<1.0 mmol/l in males; <1.3 mmol/l in females) 
WC (cm) 0.66 0.59-0.73  81.3 53.3 77.4 0.3075  0.63 0.60-0.67  81 65.6 55.8 0.2138 
WHtR 0.66 0.59-0.72 0.84 0.48 52.2 75.8 0.2799  0.62 0.58-0.66 0.004 0.53 59.1 59.8 0.1896 
 
Impaired Fasting Blood Glucose (>5.5 mmol/l) or taking glucose-lowering medication 
WC (cm) 0.63 0.57-0.69  78.5 53.2 70.3 0.235  0.62 0.58-0.66  84.3 59.5 62.0 0.2143 
WHtR 0.63 0.56-0.69 0.73 0.51 36.7 86.1 0.228  0.62 0.58-0.66 0.71 0.52 65.6 55.3 0.2088 
 
Elevated HbA1c (>6%)  or taking glucose-lowering medication 
WC (cm) 0.66 0.59-0.74  79.6 58.1 72.4 0.305  0.71 0.67-0.74  85.7 63.7 69.5 0.3317 
WHtR 0.64 0.56-0.72 0.12 0.5 48.7 83.9 0.326  0.71 0.67-0.75 0.22 0.56 61.5 72.7 0.3428 
 
                                                            
3
 *J=(sensitivity + specificity) - 1. †ROC AUC<0.6, data not shown. ROC, receiver operated characteristic; AUC, area under the curve; CI, confidence interval; 
WC, waist circumference; WHtR, waist to height ratio; SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL-C, high density lipoprotein cholesterol; 
HbA1c, glycated haemoglobin 
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TABLE 4  
Prediction of 5 year metabolic risk using waist circumference and waist-to-height ratio in black South African men and women4 
 
       
 WC WHO  WHtR 0.5  WC PURE (Men only) 
 OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value 
       
Hypertension (SBP >140 or DBP >90 mmHg or taking antihypertensive medication)  
Men (n=155) † † † † † † 
Women (n=251) 2.3 (1.4, 4.0) 0.002 2.0 (1.2, 3.4) 0.011 -  
       
Elevated Triglycerides (>1.7 mmol/l) or on triglyceride lowering medication   
Men (n=278) 4.1 (0.9, 18.9) 0.07 3.8 (1.5, 9.2) 0.004 3.0 (1.3, 6.8) 0.01 
Women (n=412) 2.3 (1.3, 4.1) 0.006 2.2 (1.2, 4.0) 0.009 -  
       
Low HDL-C (<1.0 mmol/L in males; <1.3 mmol/l in females)    
Men (n=277) 4.0 (1.2, 14.0) 0.029 2.9 (1.3, 6.5) 0.009 2.6 (1.2, 5.7) 0.016 
Women (n=348) 4.0 (2.4, 6.6) <0.001 3.5 (2.1, 5.8) <0.001 -  
       
Impaired Fasting Blood Glucose (>5.5 mmol/l) or previous diagnosis Diabetes   
Men (n=263) † † 3.6 (1.4, 9.4) 0.01 3.8 (1.5, 10.2) 0.007 
Women (n=423) 1.9 (1.1, 3.2) 0.025 2.2 (1.2, 3.9) 0.006 -  
       
Elevated HbA1c (>6%)      
Men (n=286) † † 2.1 (1.1, 4.2) 0.031 1.5 (0.8, 2.9) 0.181 
Women (n=408) 1.7 (1.1, 2.6) 0.01 2.0 (1.3, 3.0) 0.001 -  
 
 
                                                            
4
 NS, No significant contribution to the model (likelihood ratio test); †ROC AUC<0.6. All models adjusted for age (years), current smoking status, reported alcohol 
intake (and menopausal status in women).  WCWHO – women >80 cm, men >94 cm; WCPURE – men >80 cm (taken from ROC AUC analysis in this African 
population from the PURE study).   
